NCT06237868Recruiting
rTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson's Disease
The Effects of High-Frequency Repetitive Transcranial Magnetic Stimulation on Impulse Control Disorders in Parkinson's Disease Patients on Dopamine Replacement Therapy.
Source: ClinicalTrials.gov · Last updated 20 Apr 2026
Brief summary (registry, in English)
This study's objective is to evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) over the dorsolateral prefrontal cortex (dlPFC) of patients with Parkinson's Disease (PD) who experience impulse control disorders (ICDs) on impulse control symptoms and cognitive behaviors linked to ICDs: reinforcement learning and delay-discounting. This is a randomized sham-controlled cross-over trial. All patients will undergo a session of active rTMS and a session of sham rTMS, with the order of sessions randomized across participants. Following recruitment and eligibility screening, the eligible participants will undergo two sessions of rTMS (active and sham), immediately followed by neurocognitive tasks and questionnaires, no more than 1-2 weeks apart. Each session will have a duration of approximately 1-1.5 hours.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 22 Jan 2024
- Start date
- 1 May 2024
- Primary completion date
- May 2027
- Lead sponsor
- West Virginia University
- Diseases
- Parkinson disease
- NCT number
- NCT06237868
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 1 May 2024 to the primary completion date, May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of seizures or epilepsy
- History of brain lesions (such as multiple sclerosis, tumor) reported
- History of vascular issues in the brain, such as stroke
- History of a moderate to severe traumatic brain injury
- Meeting the criteria for a major psychiatric illness such as schizophrenia or depression (BDI score of 14 or higher).
- Having significant cognitive impairment (assessed by MoCA, cutoff score of 20) (Nasreddine, et al., 2005)
- Current use of substances or medications known to significantly reduce seizure threshold.
Other
- Having had TMS done in the recent past (within a year)
- Pregnancy assessed in female patients
- Intracranial metallic objects (except for dental fillings)
Who the study is looking for
- Clinician-confirmed diagnosis of PD
- Ability to provide informed consent, written and verbal
- Clinician-diagnosed impulse control disorder or impulse control behaviors including punding/hobbyism and dopamine dysregulation syndrome
- A Beck Depression Inventory (BDI) (Beck et al., 1961) score of 14 or lower
- A Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) score of 20 or higher
- On dopamine-replacement therapy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| West Virginia University Hospitals Coordinator of this site? Confirm its status | Morgantown | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.